GLP-1/GIP/NPY2 receptor (triple)

Class

Triple GLP-1/GIP/NPY2 receptor agonist

This mechanism describes a single peptide engineered to activate three distinct receptors: the GLP-1 receptor, the GIP receptor, and the neuropeptide Y2 receptor (NPY2R). GLP-1 and GIP are incretin hormones released from the gut after eating; their receptors, when activated, stimulate insulin secretion in a glucose-dependent manner, slow gastric emptying, and act on brain centers that regulate appetite. NPY2R is a separate receptor system, normally engaged by peptide YY, that also signals satiety through hypothalamic circuits but operates through different neural pathways than the incretins. Combining agonism at all three receptors is intended to produce weight loss and metabolic improvement that exceeds what activating the incretin receptors alone can achieve, by recruiting an additional, mechanistically distinct appetite-suppressing pathway. This class of triple agonists is being explored primarily for obesity and type 2 diabetes, where excess body weight and impaired insulin secretion or action are central problems. The broad rationale for multi-receptor agonism is that metabolic disease involves multiple overlapping regulatory systems, and engaging more than one simultaneously may produce additive or synergistic benefits on body weight, glycemic control, and related cardiometabolic risk factors compared with single-receptor approaches.